Abstract
Objectives: Neoadjuvant chemotherapy is being used increasingly prior to debulking for ovarian serous carcinoma. There can be significant histopathologic alterations, sometimes making the pathologic diagnosis challenging. Methods: A MEDLINE search was performed, and articles describing the histologic changes associated with neoadjuvant chemotherapy, as well as any possible clinical impact, were reviewed. Results: The scope of histopathologic changes seen after neoadjuvant chemotherapy for ovarian serous carcinoma, as well as their possible clinical significance, is presented. Histopathologic changes included degenerative changes, increased atypia, and alterations that can make pathologic interpretation difficult, particularly if there is a lack of familiarity with these changes and lack of an available clinical history. Conclusions: More research is needed to assess whether or not there is any prognostic significance to these alterations. (J GYNECOL SURG 33:1)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
